Persimmon Leaf Extract Inhibits the ATM Activity during DNA Damage Response Induced by Doxorubicin in A549 Lung Adenocarcinoma Cells

DOI Web Site Web Site 被引用文献1件 参考文献53件
  • KAWAKAMI Kayoko
    Department of Food Science, Niigata University of Pharmacy and Applied Life Sciences
  • NISHIDA Hiroshi
    Department of Food Science, Niigata University of Pharmacy and Applied Life Sciences
  • TATEWAKI Naoto
    Department of Food Science, Niigata University of Pharmacy and Applied Life Sciences
  • NAKAJIMA Yuki
    Department of Food Science, Niigata University of Pharmacy and Applied Life Sciences
  • KONISHI Tetsuya
    Department of Food Science, Niigata University of Pharmacy and Applied Life Sciences
  • HIRAYAMA Masao
    Department of Food Science, Niigata University of Pharmacy and Applied Life Sciences

この論文をさがす

抄録

Persimmon leaf (PL) has been commonly recognized for its wide variety of health benefits. A previous study has reported that persimmon leaf extract (PLE) contained flavonols with the 2″-galloly moiety (PLEg). Galloylated homologues generically show stronger activity in their biological function, so enhanced functions can be expected for PLEg. We investigated in this present study the effect of PLEg on the cellular DNA damage checkpoint signaling to sensitize cancer chemotherapy. Treatment with PLE and PLEg significantly increased the cytotoxicity of doxorubicin (DOX) in A549 adenocarcinoma cells. PLE and PLEg reduced the phosphorylation of checkpoint proteins such as structural maintenance of chromosomes 1 (SMC1), checkpoint kinase 1 (Chk1), and p53 in DOX-treated cells. Moreover, PLE decreased the phosphorylation of ATM (ataxia telangiectasia mutated) in a dose-dependent manner. PLE, and especially PLEg, abrogated the G2/M checkpoint during DOX-induced DNA damage. These results suggest that PLEg specifically inhibited ATM-dependent checkpoint activation by DOX, and that PLEg might be a useful sensitizer in cancer chemotherapy.

収録刊行物

被引用文献 (1)*注記

もっと見る

参考文献 (53)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ